Guidelines for Selecting Normal Flow Filters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Guidelines for Selecting Normal Flow Filters
Proper selection of normal flow filters leads to increased process efficiency from early phase product development through to full-scale biopharmaceutical production.


Pharmaceutical Technology



Figure 1: The relative cost of biopharmaceutical separations. (CREDIT_PHOTO)
Normal flow filters are used widely in biopharmaceutical operations to remove colloidal material, bacteria, and viruses from growth media, buffers, and process intermediates. A modern biopharmaceutical process typically contains 40-50 normal flow filtration operations from seed culture propagation to final vial filling. As shown in Figure 1, normal flow filtration accounts for approximately one-fourth of the total cost for downstream processing. Therefore, the choice of normal flow filter(s) has a potentially large impact on the total production cost for a biotherapeutic.


Quick guide to the selection of normal flow filters
The variety of filter materials available to process development scientists is large—from depth media containing nominally-rated micron-sized filtration-matrices to validated sterile filtration membranes containing submicron-sized pores. The criteria by which one chooses the optimal filter is commonly application-specific, and it is therefore important to understand these criteria when designing experiments, analyzing data, and comparing product attributes.

In general, normal flow filtration operations can be divided into three main categories:

  • Cell culture media sterilization
  • Buffer filtration
  • Product-stream filtration.


Figure 2: Normal flow filtration in biopharmaceutical production.
Figure 2 shows a typical biopharmaceutical process and highlights where each of these filteration steps occurs.

Cell culture media sterilization

One of the first unit operations in any biopharmaceutical operation is the preparation and sterilization of cell culture media. Cell culture media are nutrient-rich, buffered solutions containing amino acids, salts, vitamins, and energy sources (e.g., glucose)—all of which are essential components for the culture of healthy cells. Over the past several decades, formulations have evolved from generic basal media supplemented with animal-derived sera, to more cell-line specific formulations that are serum-free, animal-derived component-free and chemically defined. The sterilization of these media is critical to successful cell growth and protein expression.

There are many characteristics one should look for when selecting a cell culture media filter. The following paragraphs describe some of the most important features.

Sterilizing-grade membranes. The term "sterilizing-grade filter" is defined in the FDA's document Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice (1), which describes a sterilizing-grade filter as a filter that is "validated to re-producibly remove viable microorganisms from the process stream, producing a sterile effluent." The validation of sterilizing-grade membranes is commonly performed using the procedure documented in ASTM F838-05, "Standard Test Method for Determining Bacterial Retention of Membrane Filters Utilized for Liquid Filtration" (2). To be labeled "sterilizing-grade," a filter must produce a sterile effluent when challenged with Brevundimonas diminuta (B. diminuta) at a minimum concentration of 107 colony forming units (CFU) per square centimeter (cm2 ) of membrane area. Sterile filters are nearly always constructed of one or more sheets of polymeric membrane, either in pleated or flat-sheet form.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here